CL2011002863A1 - Uso de una composicion que comprende nandrolona y un compuesto de vitamina d para preparar un medicamento parenteral util para el tratamiento o prevencion de la fragilidad en un paciente de edad avanzada; y composicion que comprende nandrolona y un compuesto de vitamina d, en un portador liquido adecuado para administracion parenteral. - Google Patents
Uso de una composicion que comprende nandrolona y un compuesto de vitamina d para preparar un medicamento parenteral util para el tratamiento o prevencion de la fragilidad en un paciente de edad avanzada; y composicion que comprende nandrolona y un compuesto de vitamina d, en un portador liquido adecuado para administracion parenteral.Info
- Publication number
- CL2011002863A1 CL2011002863A1 CL2011002863A CL2011002863A CL2011002863A1 CL 2011002863 A1 CL2011002863 A1 CL 2011002863A1 CL 2011002863 A CL2011002863 A CL 2011002863A CL 2011002863 A CL2011002863 A CL 2011002863A CL 2011002863 A1 CL2011002863 A1 CL 2011002863A1
- Authority
- CL
- Chile
- Prior art keywords
- vitamin
- compound
- nandrolone
- composition
- parenteral
- Prior art date
Links
- 229930003316 Vitamin D Natural products 0.000 title abstract 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title abstract 4
- 235000019166 vitamin D Nutrition 0.000 title abstract 4
- 239000011710 vitamin D Substances 0.000 title abstract 4
- -1 vitamin D compound Chemical class 0.000 title abstract 4
- 229940046008 vitamin d Drugs 0.000 title abstract 4
- 208000036119 Frailty Diseases 0.000 title abstract 2
- 206010003549 asthenia Diseases 0.000 title abstract 2
- 238000007911 parenteral administration Methods 0.000 title abstract 2
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 title 2
- 229960004719 nandrolone Drugs 0.000 title 2
- 239000003814 drug Substances 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000003263 anabolic agent Substances 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Método de tratamiento de la fragilidad de un paciente de edad avanzada que comprende la administración parenteral de las dosis efectivas de una combinación de esteroide anabólico y de un compuesto de vitamina D; composición farmacéutica que comprende un esteroide anabólico y un compuesto de vitamina D; un dispositivo de inyección.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09168522A EP2289555A1 (en) | 2009-08-24 | 2009-08-24 | Method of treating frailty |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011002863A1 true CL2011002863A1 (es) | 2012-04-13 |
Family
ID=42016317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011002863A CL2011002863A1 (es) | 2009-08-24 | 2011-11-14 | Uso de una composicion que comprende nandrolona y un compuesto de vitamina d para preparar un medicamento parenteral util para el tratamiento o prevencion de la fragilidad en un paciente de edad avanzada; y composicion que comprende nandrolona y un compuesto de vitamina d, en un portador liquido adecuado para administracion parenteral. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10543217B2 (es) |
| EP (2) | EP2289555A1 (es) |
| JP (2) | JP2013502457A (es) |
| KR (1) | KR20120053987A (es) |
| CN (1) | CN102421450B (es) |
| AU (1) | AU2010287043B2 (es) |
| BR (1) | BRPI1011567B1 (es) |
| CA (1) | CA2759815C (es) |
| CL (1) | CL2011002863A1 (es) |
| CO (1) | CO6460777A2 (es) |
| DK (1) | DK2470214T3 (es) |
| ES (1) | ES2425095T3 (es) |
| IL (1) | IL216456A (es) |
| MX (1) | MX2011011905A (es) |
| MY (1) | MY162621A (es) |
| NZ (1) | NZ596057A (es) |
| PL (1) | PL2470214T3 (es) |
| PT (1) | PT2470214E (es) |
| RU (1) | RU2635541C2 (es) |
| SG (1) | SG176135A1 (es) |
| UA (1) | UA107928C2 (es) |
| WO (1) | WO2011025368A1 (es) |
| ZA (1) | ZA201108056B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101970893B1 (ko) | 2017-10-18 | 2019-04-19 | 동아대학교 산학협력단 | 노쇠 여부 스크리닝 장치 |
| CN109364034B (zh) * | 2018-11-26 | 2021-05-04 | 正大制药（青岛）有限公司 | 一种骨化三醇制剂及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4308264A (en) * | 1981-01-28 | 1981-12-29 | Abbott Laboratories | Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration |
| FI934891L (fi) * | 1991-05-06 | 1993-12-03 | Procter & Gamble | Kombinerade kalcium- och vitamin d-supplement |
| US5898038A (en) * | 1996-03-19 | 1999-04-27 | Board Of Regents, The University Of Texas System | Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors |
| US6031000A (en) * | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| US7261905B2 (en) * | 1999-04-07 | 2007-08-28 | Pure Bioscience | Disinfectant and method of making |
| US6638239B1 (en) * | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
| GB0307728D0 (en) | 2003-04-03 | 2003-05-07 | Tesla Engineering Ltd | Coil structure for magnetic resonance imaging |
| US8795693B2 (en) * | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| FR2860236B1 (fr) * | 2003-09-25 | 2006-01-06 | Theraptosis | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique |
| EP1896134A2 (en) * | 2005-06-13 | 2008-03-12 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
| SI3095447T1 (sl) * | 2006-02-03 | 2022-02-28 | Opko Renal, Llc | Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3 |
| CA2558202A1 (en) * | 2006-09-14 | 2006-11-23 | Reinhold W. Vieth | Vitamin d compositions and method of administration to infants |
| RU2363488C1 (ru) * | 2007-11-26 | 2009-08-10 | Закрытое акционерное общество "Эксесс Байосаинс" | Фармацевтическая композиция на основе пептида, регулирующего нарушения ангиогенеза, и способ ее применения |
| US9259430B2 (en) * | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| RU2410392C2 (ru) * | 2009-02-16 | 2011-01-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН | Дипептидные миметики нейротрофинов ngf и bdnf |
-
2009
- 2009-08-24 EP EP09168522A patent/EP2289555A1/en not_active Ceased
-
2010
- 2010-08-23 MX MX2011011905A patent/MX2011011905A/es active IP Right Grant
- 2010-08-23 JP JP2012526677A patent/JP2013502457A/ja active Pending
- 2010-08-23 US US13/318,650 patent/US10543217B2/en not_active Expired - Fee Related
- 2010-08-23 PL PL10747526T patent/PL2470214T3/pl unknown
- 2010-08-23 NZ NZ596057A patent/NZ596057A/xx not_active IP Right Cessation
- 2010-08-23 WO PCT/NL2010/050524 patent/WO2011025368A1/en not_active Ceased
- 2010-08-23 SG SG2011084944A patent/SG176135A1/en unknown
- 2010-08-23 DK DK10747526.1T patent/DK2470214T3/da active
- 2010-08-23 ES ES10747526T patent/ES2425095T3/es active Active
- 2010-08-23 PT PT107475261T patent/PT2470214E/pt unknown
- 2010-08-23 RU RU2011146830A patent/RU2635541C2/ru active
- 2010-08-23 EP EP10747526.1A patent/EP2470214B1/en not_active Not-in-force
- 2010-08-23 UA UAA201113554A patent/UA107928C2/ru unknown
- 2010-08-23 BR BRPI1011567-6A patent/BRPI1011567B1/pt not_active IP Right Cessation
- 2010-08-23 KR KR1020117026830A patent/KR20120053987A/ko not_active Ceased
- 2010-08-23 CA CA2759815A patent/CA2759815C/en not_active Expired - Fee Related
- 2010-08-23 MY MYPI2011005129A patent/MY162621A/en unknown
- 2010-08-23 AU AU2010287043A patent/AU2010287043B2/en not_active Ceased
- 2010-08-23 CN CN201080020393.2A patent/CN102421450B/zh not_active Expired - Fee Related
-
2011
- 2011-11-02 ZA ZA2011/08056A patent/ZA201108056B/en unknown
- 2011-11-14 CL CL2011002863A patent/CL2011002863A1/es unknown
- 2011-11-17 CO CO11156685A patent/CO6460777A2/es not_active Application Discontinuation
- 2011-11-17 IL IL216456A patent/IL216456A/en active IP Right Grant
-
2015
- 2015-10-15 JP JP2015203528A patent/JP6279529B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2470214B1 (en) | 2013-05-15 |
| IL216456A0 (en) | 2012-01-31 |
| ZA201108056B (en) | 2012-07-25 |
| EP2470214A1 (en) | 2012-07-04 |
| PT2470214E (pt) | 2013-08-27 |
| JP2013502457A (ja) | 2013-01-24 |
| CO6460777A2 (es) | 2012-06-15 |
| UA107928C2 (en) | 2015-03-10 |
| BRPI1011567A2 (pt) | 2016-04-05 |
| JP6279529B2 (ja) | 2018-02-14 |
| AU2010287043B2 (en) | 2014-11-06 |
| RU2635541C2 (ru) | 2017-11-13 |
| RU2011146830A (ru) | 2013-10-10 |
| US20120196837A1 (en) | 2012-08-02 |
| ES2425095T3 (es) | 2013-10-11 |
| AU2010287043A1 (en) | 2011-11-10 |
| KR20120053987A (ko) | 2012-05-29 |
| DK2470214T3 (da) | 2013-08-12 |
| NZ596057A (en) | 2013-07-26 |
| CA2759815C (en) | 2018-06-12 |
| PL2470214T3 (pl) | 2013-12-31 |
| IL216456A (en) | 2017-04-30 |
| MY162621A (en) | 2017-06-30 |
| JP2016011313A (ja) | 2016-01-21 |
| CA2759815A1 (en) | 2011-03-03 |
| US10543217B2 (en) | 2020-01-28 |
| MX2011011905A (es) | 2012-01-30 |
| EP2289555A1 (en) | 2011-03-02 |
| WO2011025368A1 (en) | 2011-03-03 |
| SG176135A1 (en) | 2011-12-29 |
| CN102421450A (zh) | 2012-04-18 |
| CN102421450B (zh) | 2015-09-09 |
| BRPI1011567B1 (pt) | 2019-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016000194A8 (pt) | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila | |
| CL2012002356A1 (es) | Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras. | |
| AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| CO6361944A2 (es) | Combinacion de una insulina y un agonista de glp-1 | |
| MX2016004316A (es) | Inhalador de polvo seco. | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| MX2015002378A (es) | Composicion ansiolitica, formulacion y metodo de uso. | |
| CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
| MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
| CR20140005A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| CL2012000319A1 (es) | Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística. | |
| CO6410278A2 (es) | Disoluciones pediátricas que continen un beta-bloqueante | |
| GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
| EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
| MX370898B (es) | Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| AR088204A1 (es) | Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina | |
| BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
| PY1330684A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. | |
| BR112012014107B8 (pt) | sistema terapêutico transdérmico (tts) e processo de produção de tts | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington |